Detection of Aerosolized Mycobacterium tuberculosis DNA From Adults Being Investigated for Pulmonary Tuberculosis via an Electrostatic Sampler in a South African Primary Care Setting - Takeaways - MDSpire

Detection of Aerosolized Mycobacterium tuberculosis DNA From Adults Being Investigated for Pulmonary Tuberculosis via an Electrostatic Sampler in a South African Primary Care Setting

  • By

  • Jay Achar

  • Rouxjeane Venter

  • Jamie van Schalkwyk

  • Zandile Booi

  • Zama Mahlobo

  • Zaida Palmer

  • Nuno Rufino de Sousa

  • Knut Lönnroth

  • James A Seddon

  • Antonio Gigliotti Rothfuchs

  • Grant Theron

  • September 24, 2025

  • 0 min

Share

  • 1

    Detection of Mycobacterium tuberculosis DNA in respiratory aerosols is feasible in primary care settings using the TB Hotspot Detector.

  • 2

    Among 137 participants, aerosol Mtb DNA detection sensitivity was 46.6% and specificity was 76.5% compared to sputum results.

  • 3

    Factors associated with aerosol Mtb DNA detection included male sex and higher sputum Ultra semiquantitative results.

  • 4

    Environmental samples showed 30% aerosol Mtb DNA detection, indicating potential nosocomial transmission risks.

  • 5

    Electrostatic aerosol sampling may help identify predictors of tuberculosis transmission and improve diagnostic strategies.

Original Source(s)

Detection of Aerosolized Mycobacterium tuberculosis DNA From Adults Being Investigated for Pulmonary Tuberculosis via an Electrostatic Sampler in a South African Primary Care Setting

  • by Jay Achar, Rouxjeane Venter, Jamie van Schalkwyk, Zandile Booi, Zama Mahlobo, Zaida Palmer, Nuno Rufino de Sousa, Knut Lönnroth, James A Seddon, Antonio Gigliotti Rothfuchs, Grant Theron

  • September 24, 2025

Related Content

Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults: A Cluster Randomized Crossover Study

Pediatricians at the Perioperative Helm

Pediatricians “uniquely positioned” to take active role in preanesthesia planning, says revised American Academy of Pediatrics report

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.